Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,354,169 shares of the biopharmaceutical company's stock after selling 19,485 shares during the quarter. American Century Companies Inc. owned about 1.07% of Alnylam Pharmaceuticals worth $329,063,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its holdings in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 143 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $26,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $30,000. Robeco Institutional Asset Management B.V. boosted its stake in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 12,513 shares during the period. Finally, V Square Quantitative Management LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $0.18 on Thursday, hitting $261.73. The company had a trading volume of 529,910 shares, compared to its average volume of 897,553. The stock has a market capitalization of $33.11 billion, a price-to-earnings ratio of -97.66 and a beta of 0.38. The stock has a fifty day moving average price of $258.25 and a 200-day moving average price of $193.82. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analysts' expectations of $447.22 million. During the same period in the previous year, the firm earned ($2.21) EPS. The firm's quarterly revenue was up 107.0% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ALNY. Leerink Partners boosted their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a "market perform" rating in a research report on Tuesday, June 25th. HC Wainwright restated a "buy" rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, August 30th. Citigroup increased their target price on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an "equal weight" rating in a research note on Friday, August 2nd. Finally, Barclays upped their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Seven analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $279.14.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 32,450 shares of the firm's stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company's stock, valued at approximately $30,013.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the business's stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now owns 136 shares of the company's stock, valued at approximately $30,013.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the firm's stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares of the company's stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 103,148 shares of company stock valued at $25,658,824. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.